Derivation, validation, and clinical relevance of a pediatric sepsis phenotype with persistent hypoxemia and shock

3

L. Nelson Sanchez-Pinto^{1,2*}; Tellen D. Bennett³; Emily Stroup⁴; Yuan Luo²; Mihir Atreya⁵; Juliane
Bubeck Wardenburg⁶; Grace Chong⁷; Alon Geva⁸; E. Vincent S. Faustino⁹; Reid W. Farris¹⁰;
Mark Hall¹¹; Colin Rogerson¹²; Sareen Shah¹³; Scott L. Weiss¹⁴; Robinder G. Khemani¹⁵

- ¹Department of Pediatrics, Northwestern University Feinberg School of Medicine and Ann &
- 9 Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; ²Department of Preventive
- 10 Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;
- ³Departments of Biomedical Informatics and Pediatrics, University of Colorado School of
- 12 Medicine, Aurora, CO, USA; ⁴Department of Pharmacology, Northwestern University Feinberg
- 13 School of Medicine, Chicago, IL, USA; ⁵Department of Pediatrics, University of Cincinnati
- 14 College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA;
- ⁶Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA;
- 16 ⁷Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL, USA;
- ⁸Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital,
- 18 Boston, MA, USA; Computational Health Informatics Program, Boston Children's Hospital,
- Boston, MA, USA; Department of Anaesthesia, Harvard Medical School, Boston, MA, USA;
- ⁹Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA; ¹⁰Department of
- 21 Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA;
- ¹¹Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital,
- 23 Columbus, OH, USA; ¹²Department of Pediatrics, Indiana University School of Medicine, Riley
- Hospital for Children, Indianapolis, IN, USA; ¹³Department of Pediatrics, Cohen Children's
- 25 Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde
- 26 Park, NY, USA; ¹⁴Department of Anesthesiology and Critical Care, Children's Hospital of
- 27 Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA;
- ¹⁵Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Los Angeles,
- 29 Los Angeles, CA, USA.
- 30

31 ***Corresponding Author**:

- 32 L. Nelson Sanchez-Pinto, MD, MBI
- 33 Division of Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago
- 34 225 E. Chicago Ave, Box 73, Chicago, IL, 60611, USA
- 35 Phone: 312-227-4912; Email: lsanchezpinto@luriechildrens.org
- 36
- 37 Word count: 3,445
- 38
- 39 **Key words**: Critical Care; Pediatrics; Sepsis; Organ Dysfunction; Precision Medicine.
- 40
- 41
- 42
- 43

44

45 ABSTRACT

46 Background

- 47 Untangling the heterogeneity of sepsis in children and identifying clinically relevant phenotypes
- 48 could lead to the development of enrichment strategies and targeted therapies. In this study, our
- 49 aim was to analyze the organ dysfunction-based trajectories of children with sepsis-associated
- 50 multiple organ dysfunction syndrome (MODS) to identify and characterize reproducible and
- 51 clinically relevant sepsis phenotypes using a data-driven approach.

52 Methods

- 53 We collected data from patients admitted with suspected infections to 13 pediatric intensive care
- units (PICUs) in the U.S. between 2012-2018. We used subgraph-augmented nonnegative
- 55 matrix factorization to identify candidate trajectory-driven phenotypes based on the type,
- 56 severity, and progression of organ dysfunction in the first 72 hours of PICU admission. We
- 57 analyzed the candidate phenotypes to determine reproducibility as well as prognostic,
- 58 therapeutic, and biological relevance.

59 Results

- 60 Overall, 38,732 children had suspected infection, of which 15,246 (39.4%) had sepsis-
- associated MODS. Amongst patients with sepsis-associated MODS, 1,537 (10.1%) died in the
- 62 hospital. We identified an organ dysfunction trajectory-based phenotype (which we termed
- 63 *persistent hypoxemia and shock*) that was highly reproducible, had features of systemic
- 64 inflammation and coagulopathy, and was independently associated with higher mortality. In a
- 65 propensity score matched analysis, patients with the *persistent hypoxemia and shock*
- 66 phenotype appeared to have a higher likelihood to benefit from adjuvant therapy with
- 67 hydrocortisone and albumin than other patients. When compared to other high-risk clinical
- 68 syndromes, the *persistent hypoxemia and shock* phenotype only overlapped with 50 to 60% of
- 69 patients with septic shock, those with moderate-to-severe pediatric acute respiratory distress

70	syndrome, or those in the top tertile of organ dysfunction burden, suggesting that it represents a
71	distinct clinical phenotype of sepsis-associated MODS with a disproportionately high risk of
72	mortality.
73	Conclusions
74	We derived and validated the persistent hypoxemia and shock phenotype, a trajectory-based
75	organ dysfunction phenotype which is highly reproducible, clinically relevant, and associated
76	with heterogeneity of treatment effect to common adjuvant therapies. Further validation is
77	warranted. Future studies are needed to validate this phenotype, assess whether it can be
78	predicted earlier in the course, study possible biological mechanisms underlying it, and
79	investigate candidate therapeutic targets.
80	
81	Word count: 341
82	
83	
84	
85	
86	
87	
88	
89	
90	
01	
91	
92	
93	

94

95 INTRODUCTION

96 Sepsis is the most common cause of multiple organ dysfunction syndrome (MODS) in children,

- 97 which in turn frequently leads to death [1–4]. Although respiratory failure is the leading organ
- 98 dysfunction associated with pediatric sepsis and sepsis-related deaths [5,6], significant

99 heterogeneity exists in the clinical presentation and underlying pathobiology of children with

- sepsis [7,8]. Untangling the clinical and biological heterogeneity in sepsis and acute respiratory
- 101 distress syndrome (ARDS) has been identified by the American Thoracic Society as a major

102 research priority in the path towards precision medicine in critical care [9].

103

104 A major challenge for untangling the heterogeneity of sepsis stems from the reality that the 105 pathobiology and clinical state of septic patients is dynamic [10,11]. Oftentimes, single time-106 points (such as ICU admission or onset of disease) are used to investigate this heterogeneity, 107 but this approach fails to capture the critical importance of the evolving and dynamic nature of 108 sepsis [12,13]. Data from electronic health records (EHRs) provides an attractive opportunity to 109 perform data-driven analyses that incorporate the dimension of time by leveraging the granular, 110 longitudinal clinical data from thousands of patients [10,14]. Indeed, EHR data from adults with 111 sepsis and children with MODS has been used to uncover subgroups of patients with similar 112 clinical characteristics and trajectories (often called 'phenotypes' or 'subphenotypes') that have 113 been associated with clinically relevant findings, such as distinct cytokine profiles or 114 heterogeneity of treatment effect to interventions like balanced fluids or hydrocortisone 115 administration [3,15,16]. However, no prior study has used this approach to uncover trajectory-116 based phenotypes in a large cohort of children with sepsis-associated MODS. 117

In this study, we aimed to derive and validate clinically relevant sepsis phenotypes using a datadriven approach to analyze organ dysfunction trajectories in a large, multicenter cohort of

children with sepsis-associated MODS. We hypothesized that we would identify one or more
reproducible sepsis phenotypes based on the trajectories of organ dysfunctions in the acute
phase of critical illness and that patients with similar trajectories would have distinct risk factors,
biochemical characteristics, response to adjuvant therapies, and clinical outcomes.

124

125 METHODS

126 Study design and patient population

127 This was a retrospective, multicenter, observational cohort study of children 0 to 18 years old 128 admitted to one of 13 participating U.S. pediatric intensive care units (PICUs) in the six-year 129 period between January 1, 2012 and January 1, 2018. Data for patients who had a confirmed or 130 suspected infection (i.e., received systemic antimicrobials and microbiological testing in the +/-131 24 hour time-window after the first admission to the PICU) were extracted from the EHRs of the 132 participating institutions using structured queries and underwent quality checks for conformity. 133 completeness, and plausibility using Kahn's framework [17]. Data with potential quality issues 134 were flagged and specific queries submitted back to the sites for clarification or re-extraction. 135 Validation of clinical values was assessed based on clinical standards and verification was 136 performed by comparing the distribution of values and count of variables across sites [17]. The 137 institutional review board (IRB) at Ann & Robert H. Lurie Children's Hospital of Chicago served 138 as the central IRB for this study. The reporting of this observational cohort study was performed 139 using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 140 reporting guideline [18].

141

We measured the type, severity, and change in organ dysfunction using the six subscores of the pediatric Sequential Organ Failure Assessment (pSOFA) score [1]. The pSOFA scores offers several advantages for this type of analysis, including a normalized scale that has been previously validated and shown to discriminate poor outcomes in critically ill children early in the

146 course better than other scores, as well as coverage of six key organ dysfunctions in sepsis: neurologic, cardiovascular, respiratory, hepatic, renal, and coagulation [1,19]. The pSOFA 147 148 subscores were calculated for each 24-hour period between PICU admission and 72 hours, 149 which was used as a proxy for the acute phase of illness [14,20]. Individual pSOFA subscores 150 were carried forward until they were remeasured or the patient died; otherwise, if completely 151 missing they were assumed to be normal and the corresponding subscore was assigned a 0, as 152 previously performed [21,22]. We defined patients with MODS as those with a pSOFA subscore 153 of ≥ 2 in ≥ 2 organ systems [3]. For the unsupervised analysis, we only included patients with 154 sepsis-associated MODS, which were defined as those with confirmed or suspected infections 155 on admission and MODS within 72 hours. Patients with immunocompromised status were 156 defined as those with a malignancy and/or transplant comorbidity. The comorbidities of 157 malignancy, transplantation, and technology dependence were based on the classification 158 system developed by Feudtner et al. [3,23,24]. Severity of illness on admission was measured 159 using the Pediatric Risk of Mortality (PRISM) III score [25]. The vasoactive-inotropic score was 160 calculated to determine the degree of shock [26]. The primary outcome was in-hospital mortality 161 and the secondary outcome was persistent MODS on day 7 after PICU admission (including 162 patients who died in the first week) [3].

163

164 Trajectory-based phenotyping

Patients were split into three sets based on site, resulting in one derivation set (data from 7 sites) and two external validation sets (3 sites each), which is consistent with geographic-based external validation, an approach recommended by established guidelines for clinical model development and validation [27]. We first used subgraph-augmented nonnegative matrix factorization (SANMF), an unsupervised trajectory modeling approach, to derive a set of organ dysfunction trajectory-based groups as candidate phenotypes in the derivation set, as

171 previously performed by our group in children with MODS [3]. The SANMF analysis consisted of 172 two parts: (a) subgraph mining, in which the individual trajectories of each of the six pSOFA 173 subscores over the first 72 hours were analyzed to determine common patterns of severity and 174 change of the individual organ dysfunctions across patients; and (b) nonnegative matrix 175 factorization, in which patients were grouped into candidate phenotypes based on similarity in 176 the frequency of the subgraphs. The validation and clinical relevance of these candidate 177 phenotypes was then assessed across three dimensions based on an established framework 178 described by DeMerle et al. [28]. Briefly, the validation of the candidate phenotypes was 179 performed across three dimensions: (i) reproducibility of the candidate phenotypes in the first 180 validation set using the SANMF mixture coefficient matrix to assess external validity; (ii) 181 reproducibility of the candidate phenotypes using different unsupervised trajectory modeling 182 methods in the derivation and first validation set (using repeated measures latent class analysis 183 [RM-LCA] and group-based trajectory modeling [GBTM]) to assess statistical approach validity: 184 and (iii) reproducibility of the candidate phenotypes in the second external validation set using a 185 Random Forest classifier to assess whether the SANMF-based phenotypes groups can be 186 accurately predicted in new datasets. The clinical relevance of the candidate phenotypes was 187 also assessed across three dimensions: (i) prognostic relevance based on the independent 188 association with outcomes; (ii) therapeutic relevance based on the association with response to 189 two adjuvant therapies (intravenous hydrocortisone and albumin); and (iii) pathobiological 190 relevance based on association with biochemical and clinical features linked to plausible 191 disease mechanisms and other clinical syndromes. The adjuvant therapies studied 192 (hydrocortisone and albumin) were chosen a priori because they are commonly used in sepsis 193 and have plausible mechanisms of action, but have conflicting evidence regarding their efficacy 194 [5].

195

196 Additional details on the Methods are included in the Online Data Supplement.

197

198 Statistical Analysis

199 Categorical variables were compared using the chi-squared test and continuous variables using 200 the Kruskal-Wallis test. Agreement between models was assessed using Fleiss' Kappa. Mixed 201 effects logistic regression was used to adjust for confounders when comparing the association 202 of candidate phenotypes with outcomes. The random effect was based on the study site and the 203 fixed effects included age, immunocompromised status, and severity of organ dysfunction in the 204 first 72 hours using the mean pSOFA score. Propensity score matching was used to account for 205 selection bias in the response to treatment analysis. The propensity score to receive either of 206 the studied treatments in the first 24 hours of admission was based on the risk factors that were 207 significantly associated with a higher likelihood of receiving the treatment. To limit the influence 208 of survival bias on whether a patient received or did not receive a treatment, only patients alive 209 for at least 24 hours were included in the propensity matched analysis. A sensitivity analysis of 210 the therapeutic relevance of phenotype membership in all patients was performed using inverse 211 probability treatment weighting (IPTW). Survival analysis to 28 days was performed using 212 Kaplan-Meier curves and Cox regression analysis. Statistical significance was set at p<0.05. 213 Data were analyzed using R version 4.0 (R Project for Statistical Computing, Vienna, Austria) 214 and STATA, version 16 (Stata Corp LLC, College Station, TX).

215

216 RESULTS

217 Study population

There were 38,732 children with suspected or confirmed infection on admission to the PICU. Of those, 15,246 (39.4%) had sepsis-associated MODS, of whom 1,537 (10.1%) died in the hospital. Sites contributed a median of 1,167 patients with sepsis-associated MODS

221 (interquartile range [IQR] 837, 1596). The median unadjusted site-specific in-hospital mortality

was 9.9% (IQR 8.2%, 13.1%), which was significantly different across sites (p<0.001). Table E1

223 presents the clinical characteristics and outcomes of patients with and without sepsis-

associated MODS in the cohort. Children with sepsis-associated MODS were randomly split by

site into a derivation set (7 sites with 7,503 patients), a first external validation set (3 sites with

- 3,484 patients), and a second external validation set (3 sites with 4,259 patients).
- 227

228 Derivation of trajectory-based candidate phenotypes using SANMF

229 Subgraph mining uncovered 776 frequent subgraphs representing individual organ dysfunction 230 trajectories in patients with sepsis-associated MODS in the derivation set. 7.448 patients (99.3%) 231 of the derivation set) had at least one frequent subgraph and were included in the SANMF 232 analysis. In the SANMF analysis, patients were separated into four trajectory-based groups 233 based on the cophenetic correlation and the group size. Groups 1, 3, and 4 had an overall 234 trajectory towards recovery of their organ dysfunctions in the first 72 hours (Figure E1) and 235 associated in-hospital mortalities in the 4.3%-6.3% range. Group 2 represented the only high-236 risk group with an in-hospital mortality of 20.9% and was characterized by a trajectory of 237 persistent organ dysfunction in the first 72 hours, predominantly respiratory, neurologic, and 238 cardiovascular dysfunctions (Table E2).

239

240 Reproducibility of the candidate phenotypes

Reproducibility of the SANMF groups in an external validation set was performed by applying
the SANMF mixture coefficient matrix from the derivation set to the frequent subgraph counts of
the first validation set. This demonstrated very reproducible distributions (i.e. proportion of
patients in each group) and associated clinical outcome across the derivation and first validation
sets (Table E2).

246

We then compared the overlap of the four SANMF-derived groups with the trajectory groups
derived using RM-LCA and GBTM. Only SANMF Group 2 had significant overlap with the

groups derived by RM-LCA and GBTM (Table E3). Specifically, RM-LCA Class 3 had a 78%
overlap with SANMF Group 2 and GBTM Group 4 had 79% overlap with SANMF Group 2. The
agreement between the models for these three groups was moderate (Fleiss' Kappa = 0.5,

p<0.001). All other overlaps ranged from 1 to 48% and had poor agreement.

253

254 Clinical characterization and external reproducibility using a classifier

SANMF Group 2 was selected for further characterization as a sepsis phenotype because of its
association with poor outcomes and its reproducibility across an external validation set and after
using three different unsupervised trajectory modeling approaches. Based on the type, severity,
and trajectory of the organ dysfunctions associated with the phenotype, we labeled it *persistent hypoxemia and shock* and grouped the rest of the patients under the label *other sepsis*-*associated MODS* (Figure 1).

261

262 We then trained a Random Forest classifier on the derivation set using the 18 daily pSOFA 263 subscores as features (6 subscores per day for 3 days) and the persistent hypoxemia and 264 shock phenotype as the outcome. The classifier had excellent performance at predicting the 265 persistent hypoxemia and shock phenotype in the first validation set (area under the curve = 266 0.97, 95% confidence interval [CI] 0.96-0.97). The variable importance for the Random Forest is 267 presented in Figure E2. When the model was applied to the second external validation set, 268 patients classified as *persistent hypoxemia and shock* had a similar distribution, severity of 269 illness, and outcomes when compared to patients with the phenotype in the derivation set and 270 first validation set, with some differences in the rate of comorbidities and organ support use 271 reflective of the baseline populations in the different sites (Table E4). Table 1 presents the 272 clinical characteristics and outcomes of patients with *persistent hypoxemia and shock* 273 phenotype compared to patients with other sepsis-associated MODS in the entire cohort.

274

275 **Prognostic relevance**

In the mixed effects model, after adjusting for age, immunocompromised state, and mean
pSOFA score in the first 72 hours, the *persistent hypoxemia and shock* phenotype was
associated with a four-fold higher odds of in-patient mortality and a two-fold higher odds of
persistent MODS at 7 days (Table 2). Figure E3 presents the Kaplan-Meier survival curve of the *persistent hypoxemia and shock* phenotype compared to patients with other sepsis-associated
MODS.

282

283 Therapeutic relevance

284 Overall, 14.983 patients survived for >24 hours and were included in the propensity matched 285 analysis. The risk factors associated with higher likelihood of receiving hydrocortisone or 286 albumin were: age, immunocompromised status, admission source, PRISM III score, 287 vasoactive-inotropic score (VIS), and study site (Tables E5-E7). We used those factors to 288 perform the propensity score matching (PSM) analysis. Using PSM, we matched 1,648 patients 289 who received hydrocortisone (95%), and 1,162 patients who received albumin (100%) to 290 untreated controls with similar propensity scores. Adequate covariate balance was achieved in 291 both the hydrocortisone (Figure E4) and albumin (Figure E6) analyses. We found a significant 292 interaction between the *persistent hypoxemia and shock* phenotype and both hydrocortisone 293 and albumin use: treated patients with the phenotype had lower mortality and less MODS at 7 294 days compared to patients with other sepsis-associated MODS (Table 3). The Kaplan-Meier 295 curves of treated and matched untreated patients with or without the persistent hypoxemia and 296 shock phenotype are presented in Figures E5 and E7.

297

In the sensitivity analysis using IPTW in the entire cohort with the same risk factors as in the PSM analysis, the interaction between the *persistent hypoxemia and shock* phenotype and hydrocortisone or albumin use were associated with lower in-hospital mortality (p<0.001).

301

302 Pathobiological relevance

- 303 Patients with the *persistent hypoxemia and shock* had more systemic inflammation,
- 304 coagulopathy, and signs of hypoperfusion than patients with other sepsis-associated MODS
- 305 (Table 4). Among the 689 patients (4.5%) who had a ferritin level obtained, the majority of
- 306 patients with *persistent hypoxemia and shock* had hyperferritinemia, with more than half
- 307 reaching levels >1000 ng/mL (Table 4).

308

- 309 When compared to other high-risk clinical syndromes in the first 72 hours of admission, the
- 310 *persistent hypoxemia and shock* phenotype overlapped with 55% of patients meeting septic

311 shock criteria, 54% of patients meeting moderate-to-severe pediatric ARDS criteria, and 62% of

312 patient in the top tertile of organ dysfunction burden based on the mean pSOFA score (Table

313 E8).

314

Finally, the *persistent hypoxemia and shock* phenotype was more common in younger patients, especially <1 year old, where the prevalence was 36-45% compared to 28-32% in the older age groups (Table E9).

318

319 DISCUSSION

In this study, we derived and validated the *persistent hypoxemia and shock* phenotype in children with sepsis-associated MODS. This trajectory-based sepsis phenotype had features of systemic inflammation and coagulopathy, was present in approximately one third of children with sepsis-associated MODS, and was independently associated with mortality. Classification of this phenotype was highly reproducible in two external validation sets and using various statistical methods for trajectory modeling. Additionally, in a propensity score analysis, patients with *persistent hypoxemia and shock* appeared to have a higher likelihood to benefit from

327 adjuvant therapy with hydrocortisone and albumin when compared to other patients with sepsis-328 associated MODS. Finally, the *persistent hypoxemia and shock* phenotype overlapped with only 329 about half of the patients with septic shock, half of those with moderate-to-severe pediatric 330 ARDS, and less than two thirds of those with the highest organ dysfunction burden based on the 331 mean pSOFA score in the first 72 hours. These latter findings highlight the fact that this 332 phenotype does not simply describe the sickest patients or those recognizable as septic shock 333 or ARDS at the bedside, instead it suggests that the persistent hypoxemia and shock phenotype 334 represents a distinct clinical phenotype of sepsis-associated MODS with a disproportionately 335 high risk of mortality, accounting for almost 70% of all deaths in patients in this cohort. 336 337 Prior studies have identified phenotypes with characteristics similar to the *persistent hypoxemia* 338 and shock phenotype. Knox et al. described the shock with hypoxemia and altered mental

339 status phenotype and Seymour et al. described the y phenotype in adult sepsis patients, which 340 share similar features, including hypoxemia, vasoactive dependence, inflammation, and high

mortality [12,13]. In follow up studies, the y phenotype has been found to be particularly

341

342 predominant in patients with viral and bacterial pneumonia, which are common etiologies of

343 sepsis and respiratory failure in children [29]. Calfee et al. and Dahmer et al. have also

344 described a hyperinflammatory phenotype of ARDS in adults and children, respectively, which

345 share many common features with the persistent hypoxia and shock phenotype [30,31]. Similar

to our findings, the hyperinflammatory ARDS phenotype is commonly associated with more

347 sepsis, inflammation, hypotension, and coagulopathy than other patients with ARDS [30-32].

346

350

348 Importantly, Calfee and colleagues have shown that the *hyperinflammatory* ARDS phenotype is 349 associated with heterogeneity of treatment effect to various common interventions, including

351 described a high-risk phenotype with severe hypoxemia and shock in children with MODS (both

ventilator strategies and fluid management [30,33,34]. Additionally, our group previously

352 with and without sepsis) in a two-center study [3]. On a related concept, Villar et al. performed

an enrichment strategy in their ARDS randomized controlled trial by only enrolling adult patients
who had persistent hypoxemia 24 hours after initial ARDS diagnosis and found that patients
who met that persistent hypoxemia criteria and received dexamethasone had a significantly
lower mortality than controls [35]. Finally, Carcillo et al. have described the hyperferritinemic
response in sepsis as a distinct, high-risk phenotype characterized by macrophage activation
that is potentially susceptible to anti-cytokine therapy [8,36,37]. Importantly, macrophage
activation appears to be a key mechanism in sepsis-related lung injury [38–41].

360

361 Our findings have important implications. While risk stratifying critically ill children with infections 362 and sepsis early in the course is important for diagnostic purposes, the clinical reality is that 363 most children with sepsis will suffer their worst degree of MODS on the day of admission. Most 364 of them, even those with significant organ dysfunction, will tend to follow a trajectory of recovery 365 after admission, as observed in our cohort and in previous studies [4,42]. Thus, understanding 366 which children with sepsis will have a trajectory of persistent or worsening organ dysfunction, 367 what patterns of dysfunction are expected in those children, and why they display those patterns 368 from a pathobiological standpoint, become guestions of paramount importance. In our study we 369 have identified a high-risk, highly reproducible trajectory-based phenotype of pediatric sepsis 370 with both prognostic and therapeutic relevance. However, the persistent hypoxemia and shock 371 phenotype requires longitudinal information for patient classification. In order for this type of 372 classification to be clinically useful it would need to be predicted earlier in the clinical course. 373 Prediction of phenotype membership is the next, important step in this line of research and 374 could be performed through a combination of machine learning approaches using EHR data 375 [43], rapid-turnaround biomarkers (including ferritin and novel cytokine profiles) [44], and other 376 physiological markers like low heart rate variability, which is associated with pro-inflammatory 377 states and progressive organ dysfunction [45,46].

378

379 Our study has several strengths and limitations. We performed our analysis using a large, 380 granular, multicenter cohort with wide geographic and racial-ethnic representation of children in 381 the United States. Furthermore, we derived and validated the *persistent hypoxemia and shock* 382 phenotypes using data that was partitioned by study sites, which allowed us to test the external 383 validity and generalizability of the phenotype. However, our dataset was observational in nature, 384 and thus susceptible to selection bias and the uncertainty introduced by missing data. While we 385 used standard approaches to ensure data quality, deal with missing data, and adjust for 386 confounders, further validation of our findings is needed. Finally, our therapeutic relevance 387 analysis using propensity scoring is susceptible to residual confounding and must be interpreted 388 with caution. 389 390 In conclusion, we derived and validated the persistent hypoxemia and shock phenotype, a 391 trajectory-based organ dysfunction phenotype which was present in a third of children with 392 sepsis-associated MODS and associated with more than two thirds of deaths. This phenotype is 393 associated with systemic inflammation and coagulopathy, is independently associated with 394 higher mortality, and is associated with heterogeneity of treatment effect to common adjuvant 395 therapies. Future studies are needed to ascertain the reproducibility of this phenotype, assess 396 whether it can be predicted earlier in the course, further study the possible biological mechanisms underlying it, and investigate candidate therapeutic targets. 397 398 399 400 401 402 403

405 **ACKNOWLEDGEMENTS**

- 406 The authors would like to acknowledge and thank the late Dr. Hector Wong (1963-2022), who
- 407 was an early collaborator and supporter of this work.

408

409 AUTHOR CONTIRBUTIONS

- 410 Concept, design and drafting of manuscript. LNS; Analysis: LNS, ES; Acquisition and/or
- 411 interpretation of the data, revising manuscript critically for important intellectual content and final
- 412 approval of the version to be published: All authors

413

414 FUNDING

415 This study was supported by the NIH (R21HD096402, Sanchez-Pinto).

416

417 AVAILABILITY OF DATA

- 418 The datasets generated and analyzed during the current study are not publicly available due
- 419 institutional review board restrictions given that it contains personal health information, but are
- 420 available from the corresponding author on reasonable request.

421

422 **DECLARATIONS**

- The institutional review board at Ann & Robert H. Lurie Children's Hospital of Chicago
- 424 served as the central review board for this study and approved it with a waiver of425 consent.
- The authors declare no financial conflicts of interest related to this study.

427

428

430 **REFERENCES**

Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ
 Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically III Children.
 JAMA Pediatr. 2017;171:e172352.

- 434 2. Weiss SL, Balamuth F, Hensley J, Fitzgerald JC, Bush J, Nadkarni VM, et al. The
 435 Epidemiology of Hospital Death Following Pediatric Severe Sepsis: When, Why, and How
 436 Children With Sepsis Die. Pediatr Crit Care Med. 2017;18:823–30.
- 3. Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of
 Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically III Children. JAMA Netw
 Open. 2020;3:e209271.
- 440 4. Lin JC, Spinella PC, Fitzgerald JC, Tucci M, Bush JL, Nadkarni VM, et al. New or Progressive
- Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis [Internet]. Pediatric Critical
 Care Medicine. 2017. p. 8–16. Available from: http://dx.doi.org/10.1097/pcc.000000000000978
- 442 Care Medicine. 2017. p. 6–16. Available from. http://dx.doi.org/10.1097/pcc.000000000000978
- 5. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al.
 Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies
 atudy Am J Baspir Crit Care Med. 2015;101:11147, 57
- 445 study. Am J Respir Crit Care Med. 2015;191:1147–57.
- 6. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global,
 regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden
 of Disease Study. Lancet. 2020;395:200–11.
- 7. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a
 clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit
 Care Med. 2015;191:309–15.
- 452 8. Carcillo JA, Berg RA, Wessel D, Pollack M, Meert K, Hall M, et al. A Multicenter Network
 453 Assessment of Three Inflammation Phenotypes in Pediatric Sepsis-Induced Multiple Organ
 454 Failure. Pediatr Crit Care Med. 2019;20:1137–46.
- 9. Shah FA, Meyer NJ, Angus DC, Awdish R, Azoulay É, Calfee CS, et al. A Research Agenda
 for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official
 American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021;204:891–
 901.
- 459 10. Xu Z, Mao C, Su C, Zhang H, Siempos I, Torres LK, et al. Sepsis subphenotyping based on
 460 organ dysfunction trajectory. Crit Care. 2022;26:197.
- 461 11. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Endotype
 462 Transitions During the Acute Phase of Pediatric Septic Shock Reflect Changing Risk and
 463 Treatment Response. Crit Care Med. 2018;46:e242–9.
- 464 12. Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation,
 465 Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA.
 466 2019;321:2003–17.
- 467 13. Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-

468 associated multiple organ dysfunction syndrome [Internet]. Intensive Care Medicine. 2015. p.
469 814–22. Available from: http://dx.doi.org/10.1007/s00134-015-3764-7

470 14. Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying Novel
471 Sepsis Subphenotypes Using Temperature Trajectories. Am J Respir Crit Care Med.
472 2019;200:327–35.

- 473 15. Bhavani SV, Semler M, Qian ET, Verhoef PA, Robichaux C, Churpek MM, et al.
- 474 Development and validation of novel sepsis subphenotypes using trajectories of vital signs.
- Intensive Care Med [Internet]. 2022; Available from: http://dx.doi.org/10.1007/s00134-02206890-z
- 477 16. Bhavani SV, Wolfe KS, Hrusch CL, Greenberg JA, Krishack PA, Lin J, et al. Temperature
 478 Trajectory Subphenotypes Correlate With Immune Responses in Patients With Sepsis. Crit
- 479 Care Med. 2020;48:1645–53.
- 480 17. Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A Harmonized
- 481 Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic
- 482 Health Record Data. EGEMS (Wash DC). 2016;4:1244.
- 483 18. Elm E von, von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. The
- 484 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
- 485 Guidelines for Reporting Observational Studies [Internet]. PLoS Medicine. 2007. p. e296.
- 486 Available from: http://dx.doi.org/10.1371/journal.pmed.0040296

487 19. Sanchez-Pinto LN, Parker WF, Mayampurath A, Derrington S, Michelson KN. Evaluation of
488 Organ Dysfunction Scores for Allocation of Scarce Resources in Critically III Children and Adults
489 During a Healthcare Crisis. Crit Care Med. 2021;49:271–81.

20. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, et al. The use of
maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a
prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM.
Intensive Care Med. 1999;25:686–96.

- 494 21. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic
 495 Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among
- Adults With Suspected Infection Admitted to the Intensive Care Unit [Internet]. JAMA. 2017. p.
- 497 290. Available from: http://dx.doi.org/10.1001/jama.2016.20328
- 498 22. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment
 499 of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and
 500 Septic Shock (Sepsis-3). JAMA. 2016;315:762–74.
- 501 23. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions 502 classification system version 2: updated for ICD-10 and complex medical technology
- dependence and transplantation [Internet]. BMC Pediatrics. 2014. Available from:
 http://dx.doi.org/10.1186/1471-2431-14-199
- 505 24. Feinstein JA, Russell S, DeWitt PE, Feudtner C, Dai D, Bennett TD. R Package for Pediatric
 506 Complex Chronic Condition Classification. JAMA Pediatr. 2018;172:596–8.
- 507 25. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality

- 508 score. Crit Care Med. 1996;24:743–52.
- 509 26. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-
- inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass.
 Pediatr Crit Care Med. 2010;11:234–8.
- 512 27. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al.
- 513 Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis 514 (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1–73.
- 515 28. DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis Subclasses: 516 A Framework for Development and Interpretation. Crit Care Med. 2021;49:748–59.
- 517 29. Bruse N, Kooistra EJ, Jansen A, van Amstel RBE, de Keizer NF, Kennedy JN, et al. Clinical 518 sepsis phenotypes in critically ill COVID-19 patients. Crit Care. 2022;26:244.
- 30. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al.
- 520 Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two 521 randomised controlled trials. Lancet Respir Med. 2014;2:611–20.
- 31. Dahmer MK, Yang G, Zhang M, Quasney MW, Sapru A, Weeks HM, et al. Identification of
 phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class
 analysis. Lancet Respir Med. 2022;10:289–97.
- 32. Sinha P, Delucchi KL, Chen Y, Zhuo H, Abbott J, Wang C, et al. Latent class analysisderived subphenotypes are generalisable to observational cohorts of acute respiratory distress
 syndrome: a prospective study. Thorax. 2022;77:13–21.
- 528 33. Alipanah N, Calfee CS. Phenotyping in acute respiratory distress syndrome: state of the art 529 and clinical implications. Curr Opin Crit Care. 2022;28:1–8.
- 530 34. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute
- Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid
 Management Strategy. Am J Respir Crit Care Med. 2017;195:331–8.
- 35. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone
 treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
 Lancet Respir Med. 2020;8:267–76.
- 36. Carcillo JA, Kernan KK, Horvat CM, Simon DW, Aneja RK. Why and How Is
 Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia? Pediatr. Crit. Care
 Med. 2020. p. 509–12.
- 539 37. Carcillo JA, Halstead ES, Hall MW, Nguyen TC, Reeder R, Aneja R, et al. Three
- 540 Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple 541 Organ Failure Outcome. Pediatr Crit Care Med. 2017;18:513–23.
- 542 38. Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S, et al. Lung
- 543 epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-
- related apoptosis-inducing ligand [Internet]. Journal of Experimental Medicine. 2008. p. 3065–
 77. Available from: http://dx.doi.org/10.1084/jem.20080201
- 546 39. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ monocyte-derived dendritic

547 cells and exudate macrophages produce influenza-induced pulmonary immune pathology and548 mortality. J Immunol. 2008;180:2562–72.

549 40. Coates BM, Staricha KL, Koch CM, Cheng Y, Shumaker DK, Scott Budinger GR, et al.

- 550 Inflammatory Monocytes Drive Influenza A Virus–Mediated Lung Injury in Juvenile Mice
- 551 [Internet]. The Journal of Immunology. 2018. p. 2391–404. Available from:
- 552 http://dx.doi.org/10.4049/jimmunol.1701543

41. Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation
During Pneumonia and Sepsis-Associated Acute Lung Injury [Internet]. Frontiers in
Immunology. 2020. Available from: http://dx.doi.org/10.3389/fimmu.2020.01722

42. Menon K, Schlapbach LJ, Akech S, Argent A, Biban P, Carrol ED, et al. Criteria for Pediatric
Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition Taskforce.
Crit Care Med. 2022;50:21–36.

43. Maddali MV, Churpek M, Pham T, Rezoagli E, Zhuo H, Zhao W, et al. Validation and utility
of ARDS subphenotypes identified by machine-learning models using clinical data: an
observational, multicohort, retrospective analysis. Lancet Respir Med. 2022;10:367–77.

44. Carlton EF, McHugh WM, McDonough K, Sturza J, Desch K, Cornell TT. Markers of
Endothelial Dysfunction and Cytokines in High-Risk Pediatric Patients with Severe Sepsis. Am J
Respir Crit Care Med. 2020;201:380–4.

45. Badke CM, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Association Between Heart
Rate Variability and Inflammatory Biomarkers in Critically III Children. Pediatr Crit Care Med.
2022;23:e289–94.

46. Badke CM, Marsillio LE, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Development of
a Heart Rate Variability Risk Score to Predict Organ Dysfunction and Death in Critically III
Children. Pediatr Crit Care Med. 2021;22:e437–47.

571

- 573
- -
- 574
- 575
- 576
- 577
- 578
- 579

580 FIGURE LEGEND

581	Figure 1. Type, severity, and trajectory of the organ dysfunctions associated with the persistent
582	hypoxemia and shock phenotype.
583	
584	
585	
586	
587	
588	
589	
590	
591	
592	
593	
594	
595	
596	
597	
598	
599	
600	
601	

602 TABLES

603 **Table 1**. Clinical characteristics of children with the *persistent hypoxemia and shock* phenotype

604 and those with *other sepsis-associated MODS*.

	Persistent	Other Sepsis-	
	Hypoxemia and	associated MODS	
Variables	Shock (n=4,836)	(n=10,410)	
Age, years (IQR)	4.3 (1, 11.7)	5.2 (1.4, 11.8)	<0.001
Male, No. (%)	2,637 (54.5)	5,742 (55.2)	0.478
Race/Ethnicity, No. (%)			
White, Non-Hispanic	2,279 (47.1)	5,127 (49.3)	0.009
Black	870 (18.0)	1,754 (16.8)	
Hispanic	875 (18.1)	1,966 (18.9)	
Asian	213 (4.4)	424 (4.1)	
Other	599 (12.4)	1,139 (10.9)	
Comorbidities, No. (%)			
Immunocompromised	953 (19.7)	1,955 (18.8)	0.183
Technology Dependent	2,166 (44.8)	4,733 (45.5)	0.445

Admission Source, No. (%)			
Emergency Department	2,000 (41.4)	4,789 (46.0)	<0.001
Hospital Floor	1,091 (22.6)	2,305 (22.1)	
Direct/Transport	1,307 (27.0)	2,118 (20.3)	
Operating Room	438 (9.1)	1,198 (11.5)	
Season, No. (%)			
Spring	1,254 (25.9)	2,686 (25.8)	0.066
Summer	1,028 (21.3)	2,262 (21.7)	
Fall	1,063 (22.0)	2,442 (23.5)	
Winter	1,491 (30.8)	3,020 (29.0)	
Year, No. (%)			
2012-2013	1,466 (30.3)	3,117 (29.9)	0.563
2014-2015	1,601 (33.1)	3,538 (34.0)	
2016-2017	1,769 (36.6)	3,755 (36.1)	
PRISM III score (IQR)	15 (10, 23)	9 (5, 14)	<0.001
Organ support, No (%)			

Mechanical ventilation	3,787 (78.3)	5,940 (57.1)	<0.001
Vasoactive infusion	3,348 (69.2)	2,844 (27.3)	<0.001
CRRT	390 (8.1)	208 (2.0)	<0.001
ECMO	337 (7.0)	70 (0.7)	<0.001
Outcomes			
Length of stay, days (IQR)	15 [7, 29]	9 (5, 18)	<0.001
Persistent MODS on day 7, No.			<0.001
(%)	2,446 (50.6)	1,722 (16.5)	
In-hospital mortality, No. (%)	1,045 (21.6)	492 (4.7)	<0.001

605 Abbreviations: *IQR*, interquartile range; *PRISM III*, Pediatric risk of mortality version 3; *CRRT*,

606 continuous renal replacement therapy; *ECMO*, extracorporeal membrane oxygenation.

- **Table 2.** Prognostic relevance associated with the persistent hypoxemia and shock phenotype
- 618 based on the generalized linear mixed effects models.

	Adjusted OR* (95% CI) for In-	Adjusted OR* (95% CI) for
Fixed effects	Hospital Mortality	Persistent MODS on day 7
Persistent hypoxemia and	4 (2.9, 5.5)	2 (1.6, 2.6)
shock phenotype		
Mean pSOFA by 72 hours	1.4 (1.4, 1.5)	1.8 (1.7, 1.9)
Age, years	1 (0.9, 1)	1 (1, 1)
Immunocompromised	1.7 (1.2, 2.5)	1 (0.7, 1.4)

619 *The random effect was the study site

- 620 Abbreviations: OR, odds ratio; CI, confidence interval; MODS, multiple organ dysfunction
- 621 syndrome; *pSOFA*, pediatric sequential organ failure assessment.

629 **Table 3.** Therapeutic relevance associated with the *persistent hypoxemia and shock* phenotype

630 based on the propensity score matched analysis.

	Matched persistent		Matched other sepsis-		P-value
Treatment and	hypoxemia ar	าd shock	associated MODS		(interaction
outcomes	phenotype)
Received	Yes (n=772)	No (n=770)	Yes (n=876)	No (n=878)	
hydrocortisone*					
Persistent MODS	415 (53.8)	457 (59.4)	194 (22.1)	176 (20)	0.023
on day 7, No. (%)					
In-hospital mortality	190 (24.6)	239 (31)	78 (9)	71(8)	0.039
after 24h, No. (%)					
Received albumin**	Yes (n=583)	No (n=500)	Yes (n=579)	No (n=662)	
Persistent MODS	337 (57.8)	305 (61)	163 (28.2)	136 (20.5)	0.003
on day 7, No. (%)					
In-hospital mortality	143 (24.5)	168 (33.6)	53 (9)	47 (7)	0.004
after 24h, No. (%)					

- 631 *≥ 1mg/kg of intravenous hydrocortisone in the first 24 hours.
- 632 $* \ge 0.5$ g/kg of albumin infusion in the first 24 hours.
- 633 Abbreviation: *MODS*, multiple organ dysfunction syndrome.

634 **Table 4.** Biochemical characteristics of the *persistent hypoxemia and shock phenotype*

635 compared to other sepsis-associated MODS.

Variables	Patients	Persistent	Other Sepsis-	
	with	Hypoxemia and	associated	
	values	Shock (n=4,836)	MODS	
			(n=10,410)	p-value
Laboratory results, median				
(IQR)*				
Min. Abs. lymphocytes, K/uL	11,877	0.99 (0.43, 1.81)	1.17 (0.54, 2.14)	<0.001
Min. Hemoglobin, g/dL	13,292	8.3 (7.1, 9.7)	9.0 (7.5, 10.5)	<0.001
Max. WBC, K/uL	12,812	12.9 (7.8, 20.2)	11.20 (6.9, 17)	<0.001
Max. Bands, %	6,205	13 (5, 25)	9 (3, 19)	<0.001
Max. CRP, mg/dL	3,886	9.5 (3.3, 22.9)	6.7 (2.5, 18.3)	<0.001
Max. Ferritin, ng/mL	689	1102 (315, 9407)	435 (154, 2774)	<0.001
Min. Platelets, K/uL	12,768	105 (42, 199)	149 (63, 238)	<0.001
Max. INR	7,713	1.6 (1.3, 2.1)	1.3 (1.2, 1.7)	<0.001
Max. PTT, sec.	7,644	42 (33, 68)	36 (30, 47)	<0.001
Max. ALT, U/L	8,722	53 (27, 161)	40 (23, 91)	<0.001

Max. AST, U/L	8,639	86 (43, 308)	54 (32, 128)	<0.001
Max. Total Bilirubin, mg/dL	8,669	0.8 (0.3, 2.3)	0.6 (0.3, 2.1)	<0.001
Min. Albumin, g/dL	10,067	2.4 (2.0, 2.8)	2.6 (2.2, 3.1)	<0.001
Max. BUN, g/dL	14,407	15 (9, 26)	11 (7, 18)	<0.001
Max. Creatinine, g/dL	14,267	0.5 (0.3, 0.9)	0.4 (0.3, 0.6)	<0.001
Max. Glucose, g/dL	14,225	196 (143, 285)	148 (117, 206)	<0.001
Min. pH	12,037	7.21 (7.10, 7.29)	7.30 (7.23, 7.35)	<0.001
Min. Bicarbonate, mEq/L	14,584	19 (15, 22)	21 (18, 23)	<0.001
Max. Lactate, mmol/L	9,294	2.9 (1.6, 6.3)	1.8 (1.1, 3.1)	<0.001
Min. PaO ₂ , mmH	6,726	63 (52, 76)	74 (59, 95)	<0.001
Max. PaCO ₂ , mmHg	6,726	55 (45, 68)	46 (40, 54)	<0.001

636 *minimum (min.) or maximum (max.) value within 72 hours of admission, as indicated

637 Abbreviations: IQR, inter-quartile range; Abs., absolute; WBC, white blood cell count; CRP, c-

638 reactive protein ; INR, international normalized ratio; PTT, partial thromboplastin time ; ALT,

639 alanine aminotransferase; AST, aspartate aminotransferase ; BUN, blood urea nitrogen; PaO₂,

640 partial pressure of arterial oxygen; *PaCO*₂, partial pressure of arterial carbon dioxide.

641

642

643

Persistent Hypoxemia and Shock Phenotype



Other Sepsis-associated MODS

